Acute myeloid leukaemia (AML)
Funding required:
$563,118
Currently raised:
$30,745
Acute myeloid leukaemia (AML)
A highly fatal blood cancer in adults and children. By adding a newly developed NAMPT inhibitor to standard of care treatment, this project can pave the way towards a more effective treatment of poor outcome adult and paediatric AML.